* Under patent application from IBA EP16193281About IntegraLab® and Synthera® +
IntegraLab® is a fully integrated solution combining equipment and services for the establishment of radiopharmaceutical production centers. IntegraLab® includes amongst others, the building design achieving full regulatory compliance and the selection, integration, supply and installation of suitable equipment to match the customer’s radioisotopes production goals. Synthera®+ is a multi-purpose automated synthesizer for the production of 18FDG, other compounds (18FCH, 18FLT, Na18F, 68Ga peptides …). This smallest available module on the market is designed to accommodate a wide range of radiochemistry processes.



About IBA
IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company’s expertise lies in the development of nextgeneration proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA’s leading fully-integrated IntegraLab® system.Headquartered in Belgium and employing more than 1,400 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors and provides high quality services and products for oncology specialists and cancer patients. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Back to HCB News

Molecular Imaging Homepage